Published in Cancer Weekly, October 11th, 2005
This is the second analytical tool to analyze the competitive situation of breast cancer therapeutics. This updated version attends to the hormone-based therapeutics as well as the new drugs under development. As new data are emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change.
Evidence that the breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.